Literature DB >> 17340127

The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone.

D T Beattie1, M Cheruvu, N Mai, M O'Keefe, S Johnson-Rabidoux, C Peterson, E Kaufman, R Vickery.   

Abstract

This study characterized the pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, its metabolite, ADL 08-0011, and methylnaltrexone. The activities of the compounds were investigated with respect to human or guinea pig opioid receptor binding and function in recombinant cell lines and mechanical responsiveness of the guinea pig ileum. Alvimopan and ADL 08-0011 had higher binding affinity than methylnaltrexone at human mu opioid receptors (pK (i) values of 9.6, 9.6, and 8.0, respectively). The compounds had different selectivities for the mu receptor over human delta and guinea pig kappa opioid receptors. ADL 08-0011 had the highest mu receptor selectivity. With respect to their mu opioid receptor functional activity ([(35)S]GTPgammaS incorporation), methylnaltrexone had a positive intrinsic activity, consistent with partial agonism, unlike alvimopan and ADL 08-0011, which had negative intrinsic activities. Alvimopan, ADL 08-0011, and methylnaltrexone antagonized inhibitory responses mediated by the mu opioid agonist, endomorphin-1 (pA (2) values of 9.6, 9.4, and 7.6, respectively) and by U69593, a kappa opioid agonist (pA (2) values of 8.4, 7.2, and 6.7, respectively). In morphine-naive guinea pig ileum, methylnaltrexone reduced, while alvimopan and ADL 08-0011 increased, the amplitude of electrically evoked contractions and spontaneous mechanical activity. In tissue from morphine-dependent animals, alvimopan and ADL 08-0011 increased spontaneous activity to a greater degree than methylnaltrexone. The data suggested that alvimopan-induced contractions resulted predominantly from an interaction with kappa opioid receptors. It is concluded that alvimopan, ADL 08-0011, and methylnaltrexone differ in their in vitro pharmacological properties, particularly with respect to opioid receptor subtype selectivity and intrinsic activity. The clinical significance of the data from this study remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17340127     DOI: 10.1007/s00210-007-0146-x

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  51 in total

Review 1.  Incidence, prevalence, and management of opioid bowel dysfunction.

Authors:  M Pappagallo
Journal:  Am J Surg       Date:  2001-11       Impact factor: 2.565

Review 2.  Side effects of morphine administration in cancer patients.

Authors:  G Vanegas; C Ripamonti; A Sbanotto; F De Conno
Journal:  Cancer Nurs       Date:  1998-08       Impact factor: 2.592

3.  [3H]U-69593 a highly selective ligand for the opioid kappa receptor.

Authors:  R A Lahti; M M Mickelson; J M McCall; P F Von Voigtlander
Journal:  Eur J Pharmacol       Date:  1985-02-26       Impact factor: 4.432

4.  Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial.

Authors:  Daniel M Paulson; Daniel T Kennedy; Roger A Donovick; Randall L Carpenter; Maryann Cherubini; Lee Techner; Wei Du; Yuju Ma; William K Schmidt; Bruce Wallin; David Jackson
Journal:  J Pain       Date:  2005-03       Impact factor: 5.820

5.  Naloxone-induced depolarization and synaptic activation of myenteric neurons in morphine-dependent guinea pig ileum.

Authors:  S M Johnson; J T Williams; M Costa; J B Furness
Journal:  Neuroscience       Date:  1987-05       Impact factor: 3.590

6.  Studies in vitro with ICI 174,864, [D-Pen2, D-Pen5]-enkephalin (DPDPE) and [D-Ala2, NMePhe4, Gly-ol]-enkephalin (DAGO).

Authors:  L D Hirning; H I Mosberg; R Hurst; V J Hruby; T F Burks; F Porreca
Journal:  Neuropeptides       Date:  1985-02       Impact factor: 3.286

Review 7.  Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects.

Authors:  Chun-Su Yuan
Journal:  J Support Oncol       Date:  2004 Mar-Apr

8.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

Review 9.  Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.

Authors:  Andrea Kurz; Daniel I Sessler
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Acute withdrawal after bremazocine and the interaction between mu- and kappa-opioid receptors in isolated gut tissues.

Authors:  P Valeri; L A Morrone; L Romanelli; M C Amico
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

View more
  12 in total

1.  The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist.

Authors:  Pamela R Tsuruda; Ross G Vickery; Daniel D Long; Scott R Armstrong; David T Beattie
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-04       Impact factor: 3.000

2.  Discovery of Axelopran (TD-1211): A Peripherally Restricted μ-Opioid Receptor Antagonist.

Authors:  Daniel D Long; Scott R Armstrong; David T Beattie; Christina B Campbell; Timothy J Church; Pierre-Jean Colson; Sean M Dalziel; John R Jacobsen; Lan Jiang; Glenmar P Obedencio; Miroslav Rapta; Daisuke Saito; Ioanna Stergiades; Pamela R Tsuruda; Priscilla M Van Dyke; Ross G Vickery
Journal:  ACS Med Chem Lett       Date:  2019-11-26       Impact factor: 4.345

3.  Morphine stimulates platelet-derived growth factor receptor-β signalling in mesangial cells in vitro and transgenic sickle mouse kidney in vivo.

Authors:  M L Weber; C Chen; Y Li; M Farooqui; J Nguyen; T Poonawala; R P Hebbel; K Gupta
Journal:  Br J Anaesth       Date:  2013-07-02       Impact factor: 9.166

4.  Managing opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide.

Authors:  Katri Elina Clemens; Eberhard Klaschik
Journal:  Ther Clin Risk Manag       Date:  2010-03-03       Impact factor: 2.423

Review 5.  Opioid receptors in the gastrointestinal tract.

Authors:  Peter Holzer
Journal:  Regul Pept       Date:  2009-04-02

6.  Methylnaltrexone: its pharmacological effects alone and effects on morphine in healthy volunteers.

Authors:  James P Zacny; Kristen Wroblewski; Dennis W Coalson
Journal:  Psychopharmacology (Berl)       Date:  2014-05-29       Impact factor: 4.530

7.  The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity.

Authors:  Scott R Armstrong; Christina B Campbell; Carrie L Richardson; Ross G Vickery; Pamela R Tsuruda; Daniel D Long; Sharath S Hegde; David T Beattie
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-03-13       Impact factor: 3.000

8.  Methylnaltrexone crosses the blood-brain barrier and attenuates centrally-mediated behavioral effects of morphine and oxycodone in mice.

Authors:  D Matthew Walentiny; Essie Komla; Léa T Moisa; Mohammed A Mustafa; Justin L Poklis; Hamid I Akbarali; Patrick M Beardsley
Journal:  Neuropharmacology       Date:  2020-12-11       Impact factor: 5.250

9.  Recent advances in the use of opioids for cancer pain.

Authors:  Joanne Droney; Julia Riley
Journal:  J Pain Res       Date:  2009-09-23       Impact factor: 3.133

Review 10.  New approaches to the treatment of opioid-induced constipation.

Authors:  P Holzer
Journal:  Eur Rev Med Pharmacol Sci       Date:  2008-08       Impact factor: 3.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.